PriceTargets.com logo

Akili - AKLI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 825.93%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.43 As of 07/2/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for AKLI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Akili Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKLI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKLI

Analyst Price Target is $4.00
▲ +825.93% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Akili in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 825.93% upside from the last price of $0.43.

This chart shows the closing price for AKLI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Akili. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2023Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$4.00Low
1/25/2023Morgan StanleyBoost TargetEqual Weight$2.00 ➝ $3.00Low
12/28/2022Morgan StanleyInitiated CoverageEqual WeightLow
11/18/2022Bank of AmericaInitiated CoverageNeutralLow
11/15/2022Credit Suisse GroupBoost TargetOutperform$4.00 ➝ $4.50Low
10/25/2022Credit Suisse GroupInitiated CoverageOutperform$5.00Low
9/6/2022Lifesci CapitalReiterated RatingOutperformLow
9/6/2022CowenInitiated CoverageOutperformLow
9/6/2022CowenInitiated CoverageOutperformLow
(Data available from 7/27/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/28/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/27/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Akili logo
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $0.43
Low: $0.43
High: $0.43

50 Day Range

MA: $0.43
Low: $0.41
High: $0.44

52 Week Range

Now: $0.43
Low: $0.19
High: $1.25

Volume

N/A

Average Volume

2,204,574 shs

Market Capitalization

$34.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Akili?

The following equities research analysts have issued stock ratings on Akili in the last year: Credit Suisse Group AG.
View the latest analyst ratings for AKLI.

What is the current price target for Akili?

1 Wall Street analysts have set twelve-month price targets for Akili in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 825.9%. Credit Suisse Group AG has the highest price target set, predicting AKLI will reach $4.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $4.00 for Akili in the next year.
View the latest price targets for AKLI.

What is the current consensus analyst rating for Akili?

Akili currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AKLI will outperform the market and that investors should add to their positions of Akili.
View the latest ratings for AKLI.

What other companies compete with Akili?

Other companies that are similar to Akili include Semper Paratus Acquisition, Electromed, FONAR, Vivani Medical and Pro-Dex. Learn More about companies similar to Akili.

How do I contact Akili's investor relations team?

Akili's physical mailing address is 2850 W. HORIZON RIDGE PARKWAY SUITE 200, HENDERSON NV, 89052. The company's listed phone number is 650-931-6236 and its investor relations email address is [email protected]. The official website for Akili is www.akiliinteractive.com. Learn More about contacing Akili investor relations.